Investigational injection plus chemo before surgery for stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination treatment for cancer of the esophagus or stomach. It uses an investigational drug called RP2, which is injected directly into the tumor during an endoscopy, together with standard chemotherapy (FLOT), to try to shrink the tumor before surgery and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer in the esophagus, the stomach, or the junction between them, and it has not spread to other organs.
- Your cancer is at a stage where it is at least T2 (meaning it has grown into deeper layers) or has spread to nearby lymph nodes.
- You are physically able to do daily activities on your own (a score of 0 or 1 on a standard scale).
- You are healthy enough for surgery as judged by a qualified surgeon.
- Your blood counts and liver and kidney function are within normal limits.
- You have not had chemotherapy, radiation therapy, or immunotherapy for this cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
This study tests new drug combinations given before and after surgery for people with stomach or gastroesophageal cancer that can be removed but is locally advanced (has grown into nearby tissue). The goal is to see if these combinations can shrink the tumor and improve outcomes.
This trial tests giving a combination of immunotherapy, a growth factor to boost white blood cells, and chemotherapy before surgery for stomach cancer. The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.